Urol. praxi. 2017;18(5):202-204 | DOI: 10.36290/uro.2017.048

Does the standard practice confirm the efficacy of vinflunine in the treatment of metastatic urothelial carcinoma?

MUDr. Jana Katolická, Ph.D.
Onkologicko-chirurgické oddělení FN u svaté Anny, Brno

Vinflunine has been approved in Europe for second-line treatment of metastatic and advanced urothelial cancer after failure ofplatin-containing therapy. The reports from daily clinical practice with more heterogeneous patient populations present valuablesources of information on treatment modalities, risk stratification and side-effect management in this narrow indication. Theyconfirm the results from pivotal trials with regard to safety and efficacy.

Keywords: metastatic and advanced urothelial cancer after failure of platin-containing therapy, vinflunine, second line treatment

Published: December 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Katolická J. Does the standard practice confirm the efficacy of vinflunine in the treatment of metastatic urothelial carcinoma? Urol. praxi. 2017;18(5):202-204. doi: 10.36290/uro.2017.048.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol. 1997; 158: 62-67. Go to original source... Go to PubMed...
    2. Yafi FA, North S, Kassouf W. First- and second-line therapy for metastatic urothelial carcinoma of the bladder. Curr Oncol. 2011; 18(1): e25-e34. Go to original source... Go to PubMed...
    3. Bellmunt J, Théodore C, Demkov T, Komyakov B, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. Clin Oncol. 2009; 27(27): 4454-4461. Go to original source...
    4. Bellmunt J, Fougeray R, Rosenberg J, von der Maase H, Schutz F, Salhi Y, et al. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol 2013; 24: 1466-1472. Go to original source...
    5. Hegele A, Goebell P, Matz U, Neuhaus T. Monotherapy with intravenous vinflunine in patients with advanced or metastatic urothelial cancer after failure of a platinum-containing regimen: a retrospective analysis of German routine data. Urol Int 2014; 92: 174-179. Go to original source... Go to PubMed...
    6. Médioni J, Di Palma M, Guillot A, Spaeth D, Théodore Ch. Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study. BMC Cancer 2016; 16: 217. Go to original source...
    7. Castellano D, Puente J, de Velasco G, Chirivella I, Lopez-Criado P, Mohedano N, et al. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice. BMC Cancer 2014; 14: 779. Go to original source...
    8. Pistamaltzian N, Tzannis K, et al.Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by the Hellenic Genitourinary Cancer Group. Anti-Cancer Drugs 2016; 27: 48-53. Go to original source...
    9. Facchini G, Pepa CHD, Cavalliere C, et al. From Clinical trial to the Front line: Vinflunin for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples. Frontietrs in Pharmacology. 2016; 7: 110. Go to original source... Go to PubMed...
    10. Palacka P, Mego M, Obertova J, Chovanec M, Sycova-Mila Z, Mardiak J. The first Slovak experience with second-line vinflunine in advanced urothelial carcinomas. Klin Onkol 2014; 27: 429-433. Go to original source... Go to PubMed...
    11. Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 2014; 25(Suppl 3): iii40-iii48. Go to original source...
    12. Witjes JA, Compérat E, Cowan NC. Guidelines: Muscle-invasive and Metastatic Bladder Cancer. Dostupné na: http://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/.
    13. O lécích, www.olecich.cz
    14. David K, Milowsky M, Ritchey J, Carroll P, Nanus D. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol 2007; 178: 451-454. Go to original source... Go to PubMed...
    15. Stenzl A, Cowan NC, De Santis M, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Actas Urol Esp 2012; 36(8): 449-460. Go to original source...
    16. Raghavan D, Shipley WU, Garnick MMB, Russell PJ, Richie JP. Biology and management of bladder cancer. N Engl J Med. 1990; 322(16): 1129-1138. Go to original source...
    17. Serrate C, Pouessel HG, Maignan Ch, Teixeira L, Culine S. Vinflunine for the treatment of metastatic transitional cell carcinoma: recent evidence from clinical trials an observational studies. Clin Invest 2014 doi10.4155/CLI.14.15. Go to original source...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.